Rhumbline Advisers lifted its position in Clovis Oncology, Inc. (NASDAQ:CLVS) by 13.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 53,709 shares of the biopharmaceutical company’s stock after acquiring an additional 6,208 shares during the period. Rhumbline Advisers owned 0.11% of Clovis Oncology worth $4,426,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the company. Los Angeles Capital Management & Equity Research Inc. bought a new position in Clovis Oncology during the 3rd quarter valued at approximately $974,000. Capital Analysts LLC bought a new position in Clovis Oncology during the 3rd quarter valued at approximately $111,000. Candriam Luxembourg S.C.A. increased its position in Clovis Oncology by 28.7% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 217,500 shares of the biopharmaceutical company’s stock valued at $17,922,000 after buying an additional 48,500 shares in the last quarter. Prudential Financial Inc. increased its position in Clovis Oncology by 1,416.9% during the 3rd quarter. Prudential Financial Inc. now owns 66,560 shares of the biopharmaceutical company’s stock valued at $5,485,000 after buying an additional 62,172 shares in the last quarter. Finally, American Century Companies Inc. increased its position in Clovis Oncology by 14.3% during the 3rd quarter. American Century Companies Inc. now owns 70,432 shares of the biopharmaceutical company’s stock valued at $5,804,000 after buying an additional 8,786 shares in the last quarter.
A number of research firms recently weighed in on CLVS. BidaskClub lowered Clovis Oncology from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 9th. Morgan Stanley reaffirmed an “overweight” rating and set a $93.00 price objective on shares of Clovis Oncology in a research report on Thursday, August 10th. Leerink Swann reduced their price objective on Clovis Oncology to $107.00 and set an “outperform” rating for the company in a research report on Friday, August 18th. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Clovis Oncology in a research report on Friday, August 18th. Finally, Evercore ISI began coverage on Clovis Oncology in a research report on Wednesday, August 16th. They set an “in-line” rating and a $73.00 price objective for the company. Eight investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $86.15.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $63.70, for a total value of $191,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders sold 9,000 shares of company stock valued at $653,220. Corporate insiders own 12.50% of the company’s stock.
Shares of Clovis Oncology, Inc. (NASDAQ CLVS) opened at $59.31 on Tuesday. Clovis Oncology, Inc. has a fifty-two week low of $35.38 and a fifty-two week high of $99.45. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.16 and a current ratio of 3.19.
Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.06). The business had revenue of $16.81 million during the quarter, compared to the consensus estimate of $21.12 million. Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. During the same period in the previous year, the business posted ($1.70) EPS. analysts predict that Clovis Oncology, Inc. will post -7.63 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Rhumbline Advisers Increases Stake in Clovis Oncology, Inc. (CLVS)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/12/05/rhumbline-advisers-increases-stake-in-clovis-oncology-inc-clvs.html.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.